Article
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.
Antimicrobial agents and chemotherapy - 18 Oct 2023
Deroche Luc, Aranzana-Climent Vincent, Rozenholc Albane, Prouvensier Laure, Darnaud Léa, Grégoire Nicolas, Marchand Sandrine, Ploy Marie-Cécile, François Bruno, Couet William, Barraud Olivier, Buyck Julien M
Abstract excerpt
A double ampC (AmpCG183D) and ampD (AmpDH157Y) genes mutations have been identified by whole genome sequencing in a Pseudomonas aeruginosa (PaS) that became resistant (PaR) in a patient treated by ceftolozane/tazobactam (C/T). To precisely characterize the respective contributions of these mutations on the decreased susceptibility to C/T and on the parallel increased susceptibility to imipenem (IMI), mutants were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.